TMPRSS4 and gastric cancer: Therefore, the expression of TMPRSS4 may be a useful predictor for modulating the S-1 plus docetaxel therapy in patients with stage III GC, because the prognosis of TMPRSS4- negative patients at stage III was notable under only S-1 monotherapy, as the 5-year survival rate was 85%.